Key result
Single-pill amlodipine/atorvastatin plus lifestyle changes increased the attainment of combined BP and LDL-C goals compared to amlodipine alone.
Why the study?
Does amlodipine/atorvastatin single-pill therapy plus therapeutic lifestyle changes improve the attainment of combined blood pressure and LDL-C goals in hypertensive participants with additional cardiovascular risk factors?
RCT
double-blind, double-dummy
randomized
Does amlodipine/atorvastatin single-pill therapy plus therapeutic lifestyle changes improve the attainment of combined blood pressure and LDL-C goals in hypertensive participants with additional cardiovascular risk factors?
Single-pill amlodipine/atorvastatin therapy significantly improves the attainment of combined blood pressure and LDL-C goals compared to amlodipine alone in hypertensive patients with additional cardiovascular risk factors.
Answers are grounded in this paper and cite their sources.
Supports single-pill amlodipine/atorvastatin plus lifestyle changes for dual goal attainment in high-risk hypertension; extends RCT evidence for fixed-dose combinations.
TOGETHER investigated whether targeting multiple cardiovascular (CV) risk factors using single-pill amlodipine/atorvastatin (AML/ATO) and therapeutic lifestyle changes (TLC) results in greater blood pressure (BP)/lipid control and additional reduction in estimated cardiovascular disease (CVD) risk compared with blood pressure intervention only using amlodipine (AML) + TLC. TOGETHER was a 6-week, randomized, double-blind, double-dummy trial using hypertensive participants with additional CV risk factors without CVD/diabetes. Participants were randomized to either AML/ATO (5 to 10/20 mg) + TLC or AML (5 to 10 mg) + TLC. The primary end point was the difference in proportion of participants attaining both BP (<140/90 mm Hg) and low-density lipoprotein cholesterol (LDL-C) (<100 mg/dL) goals at week 6. At week 6, 67.8% of participants receiving AML/ATO + TLC attained the combined BP/LDL-C goal versus 9.6% with AML + TLC (RD [A-B]: 58.2; 95% CI [48.1 to 68.4] P < 0.001; OR: 19.0; 95% CI 9.1 to 39.6; P < 0.001). Significant reductions from baseline in LDL-C, total cholesterol and triglycerides and estimated 10-year Framingham risk were also observed. Treatment with AML/ATO was well tolerated. In conclusion, a multifactorial CV management approach is more effective in achieving combined BP/LDL-C targets as well as CV risk reduction compared with BP intervention only in this patient population.
No takes yet. Share an insight, caveat, or question.
Richard H. Grimm (2010) conducted an RCT in Hypertension with additional CV risk factors. Amlodipine/atorvastatin (AML/ATO) single-pill + therapeutic lifestyle changes (TLC) vs. Amlodipine (AML) (5 to 10 mg) + TLC was evaluated on Difference in proportion of participants attaining both BP (<140/90 mm Hg) and LDL-C (<100 mg/dL) goals at week 6 (OR 19.0, 95% CI 9.1 to 39.6, p=< 0.001). Single-pill amlodipine/atorvastatin plus lifestyle changes increased the attainment of combined BP and LDL-C goals compared to amlodipine alone.
Synapse has enriched 10 related papers. Consider them for comparative context: